AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Oruka Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SB1GL2
80.15▼ 1.00 (-1.23%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
81.15
Day's Range
79.07 – 81.15
52-Week Range
25.21 – 115.52
Volume
514.0K
Avg Volume
983.8K
Share Statistics
Shares Outstanding
Employees
68
Exchange
XNAS
Listed
2024-09-03
Share count as of July 31, 2026

Oruka Therapeutics, Inc. Common Stock (ORKA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Oruka Therapeutics, Inc. Common Stock (ORKA)
What is Oruka Therapeutics, Inc. Common Stock's Market Cap?
Oruka Therapeutics, Inc. Common Stock's Market Cap is $5.3B, based on as-reported figures from SEC (XBRL) filings.
What is Oruka Therapeutics, Inc. Common Stock's Net Income (TTM)?
Oruka Therapeutics, Inc. Common Stock's Net Income (TTM) is -$132.9M, based on as-reported figures from SEC (XBRL) filings.
What is Oruka Therapeutics, Inc. Common Stock's EBITDA?
Oruka Therapeutics, Inc. Common Stock's EBITDA is -$154.9M, based on as-reported figures from SEC (XBRL) filings.
What is Oruka Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Oruka Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -2.01, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ORKAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Other income (expense), net——
Total other income, net
Net loss
Net loss per share attributable to stockholders, basic (in Dollars per share)————
Net loss per share attributable to stockholders, Diluted (in Dollars per share)————